Halozyme Therapeutics | HALO - Ebit



Halozyme Therapeutics reported $202.44M in EBIT for its fiscal quarter ending in June of 2025.


Ebit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD 4.89M 13.19M Jun/2025
Amarin USD -16755000 707K Mar/2025
Amgen USD 2.26B 1.34B Jun/2025
Baxter International USD 272M 120M Jun/2025
Cytokinetics USD -111506000 44.12M Jun/2025
DBV Technologies USD -41110000 17.34M Jun/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Halozyme Therapeutics USD 202.44M 54.09M Jun/2025
Ionis Pharmaceuticals USD 144.78M 290.78M Jun/2025
MannKind USD -43411000 65.7M Jun/2025
Pfizer USD 2.6B 3.33B Jun/2025
United Therapeutics USD 276.9M 105.9M Jun/2025